



seraxis

Cell Therapy for Diabetes

Press Release

Seraxis Inc. announces a Commercialization grant award from the Maryland Stem Cell Research Fund (MSCRF)

Germantown, Maryland, May 11, 2017 – Seraxis Inc. today announced that it was awarded a Commercialization Program Grant from the Maryland Stem Cell Research Fund (MSCRF). The state-funded stem cell research grant will support work to characterize the long-term survival of Seraxis cell replacement therapy, SR-01, for insulin-dependent diabetes. In a proof-of-concept study, SR-01 has successfully restored normoglycemia in diabetic animal models for at least 6 months.

Seraxis recently contracted with a global Contract Research Organization (CRO) to help move SR-01 to the clinic.

About Seraxis

Seraxis is a privately held biotechnology company, incorporated in the United States and in Singapore. Its U.S. headquarters are located in Germantown, Maryland in the heart of the BioHealth Capital Region. Seraxis used proprietary technologies to develop: (1) a cell therapy that is more effective and safer than embryonic stem cell-derived therapies, and; (2) a cell encapsulation device that enables the long-term function of replacement, insulin-producing cells in an immune-competent host. Further information can be found at www.seraxis.com